The Joint Corp (JYNT) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of The Joint Corp $2.25, price $7.28, upside -69.1%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch The Joint Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range $7.28 – $107.30 · fair‑value band $1.90 – $2.53 · the $7.28 price screens above the $2.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow The Joint in your weekly email
Every Wednesday you see whether The Joint is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support.
Show more
The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. It operates through a network of franchised clinics, offering routine and affordable chiropractic adjustments using a private pay, non-insurance, cash-based model. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Stock analysis
The Joint Corp (JYNT) currently trades at $7.28, while our model-based Fair Value estimate is $2.25, 69.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $5.15 per share, and 1 of the 20 models we run sit above the $7.28 price.
Bear case: the Asset-Based group reads lowest at $0.7100, and 19 of the 20 models stay below the price. Evidence for this calculation is medium.
Scenario range: $1.90 (bear) to $2.53 (bull), the price of $7.28 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
The Joint Corp reported revenue of $54.9M in FY2025 versus $80.0M in FY2021, a compound −9.0%/yr. Reported net income was $2.9M in FY2025, compounding −21.3%/yr from FY2021.
Key figures
Market cap $104M · P/E ratio 52.0 · P/S ratio 2.75 · EPS (TTM) $0.1400 · Net margin 5.3% · Return on equity 10.6% · Return on assets (EBIT) 0.9% · Operating margin 3.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −69%, JYNT screens richer than that median.
Fair Value models
Bear $1.90Fair Value $2.25Bull $2.53
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1059 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Start year 2020 (pandemic). Over 10 years: +14.8% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−3.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → −2%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+72.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +68.8% a year for the price and +1.8% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside−69.9% · Bottom 25%
Profitability
Return on equity (TTM)10.6% · Above median
Return on assets2.3% · Below median
Net margin (TTM)6.5% · Above median
Operating margin (TTM)3.3% · Bottom 25%
Growth and dividend
Revenue growth14.4% · Above median
Balance sheet
Debt / equity0.13× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)52.0× · Priciest 25%
P/B7.07× · Priciest 25%
P/S (TTM)1.82× · Pricier than median
P/FCF318.0× · Priciest 25%
EV/EBITDA21.1× · Priciest 25%
PEG8.83× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)72· sector 26
PAST (return on equity)42· sector 31
HEALTH (low debt)93· sector 90
DIVIDEND (yield)0· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "The Joint Corp Fair Value". https://www.fairvalue-calculator.com/stock/JYNT
Frequently asked questions
Is The Joint Corp (JYNT) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $2.25 versus a price of $7.28, about −69% upside (overvalued).
What is the fair value of JYNT?
Our model-based fair value for The Joint Corp is $2.25 (as of Oct 2, 2026), built from audited fundamentals. The current price: $7.28.
What is the quality score of JYNT?
The Joint Corp has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for The Joint Corp (JYNT)?
Our model-based price target is the fair value of $2.25 (as of Oct 2, 2026) from 20 valuation models. Cautious scenario $1.90, optimistic scenario $2.53. It is a calculation from audited fundamentals, not an analyst target.
What is the The Joint Corp stock forecast for 2026?
Our models put fair value at $2.25, about −69% upside versus a price of $7.28 (overvalued). Cautious scenario $1.90, optimistic scenario $2.53. The calculation is refreshed regularly with new filings.
What is the revenue of The Joint Corp (JYNT)?
The Joint Corp reported trailing-twelve-month revenue of about $58.5M (latest available figure, as of Oct 2, 2026).
What growth is priced into The Joint Corp (JYNT)?
For today's price to be fair in a discounted-cash-flow model, The Joint Corp would have to grow free cash flow by +72.8 % per year for five years (discount rate 12.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.3 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of JYNT use?
Our models discount The Joint Corp at 12.9 %: a base by market capitalisation (micro), damped by beta 1.06, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For The Joint Corp that is +72.8 % per year a year over ten years, using the same discount rate (12.9 %) and the same formula as our fair value.
How much growth has The Joint Corp (JYNT) delivered so far?
Over the past 5 years revenue at The Joint Corp grew -1.3 % a year. The price currently implies +72.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of The Joint Corp (JYNT) growing?
The median revenue growth in the sector is +5.0 % a year. That is the yardstick for the growth priced into The Joint Corp (+72.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of The Joint Corp (JYNT)?
The free-cash-flow yield on the price is 0.32 %: that much free cash flow The Joint Corp produces per unit of market value. When it exceeds the discount rate of our models (12.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of The Joint Corp (JYNT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For The Joint Corp it is $2.25 per share (as of Oct 2, 2026), against a price of $7.28. It is the blended result of 20 valuation models (cash flow, earnings, asset, dividend).
Is The Joint Corp stock overvalued or undervalued in 2026?
As of Oct 2, 2026, JYNT trades above its calculated fair value: price $7.28, fair value $2.25, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JYNT?
No. The price is what the market pays today ($7.28); the fair value is what the company's own numbers justify ($2.25). For The Joint Corp the two are $5.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is The Joint Corp worth?
The market values The Joint Corp at about $104M (market capitalisation, as of Oct 2, 2026). Per share that is $7.28; our models calculate a fair value of $2.25 per share.
What do the bullish and bearish scenarios say about JYNT?
Our models span a range for The Joint Corp: cautious scenario $1.90, base $2.25, optimistic $2.53 per share (as of Oct 2, 2026, price $7.28). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JYNT?
The Joint Corp trades at a price-to-earnings ratio of 52.0 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.25 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 33.1 (reported for FY2025: 38.3). Other multiples: PEG 8.8, P/B 7.1, P/S 1.8, EV/EBITDA 21.1.
What is the PEG ratio of JYNT?
The PEG ratio of The Joint Corp is 8.83 (P/E divided by earnings growth, as of Oct 2, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of The Joint Corp (JYNT)?
Balance-sheet figures for The Joint Corp (as of Oct 2, 2026): return on equity 10.6%, debt of 0.13 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is JYNT from its 52-week high?
The Joint Corp trades at $7.28, about 31% below its 52-week high of $10.53 and at the low of $7.28 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $2.25 is for.
Which stocks are comparable to The Joint Corp?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is The Joint Corp stock attractive at the current price?
The data as of Oct 2, 2026: price $7.28, calculated fair value $2.25 (−69%), Quality Score 66/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JYNT calculated?
We run The Joint Corp through 20 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. The Joint Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of The Joint Corp (JYNT)?
The closing price on Oct 2, 2026 was $7.28. Our model-based fair value is $2.25, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with The Joint Corp right now?
The price sits above even our optimistic bull case ($2.53). The favourable scenario is already priced in. Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of The Joint Corp
How large is the market capitalisation of The Joint Corp (JYNT)?
The market capitalisation of The Joint Corp is $104M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of The Joint Corp (JYNT)?
The price-to-sales ratio of The Joint Corp is 2.75 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of The Joint Corp (JYNT)?
Earnings per share at The Joint Corp are $0.1400 (price ÷ EPS = P/E 52.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of The Joint Corp (JYNT)?
The net margin of The Joint Corp is 5.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of The Joint Corp (JYNT)?
The return on equity (ROE) of The Joint Corp is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of The Joint Corp (JYNT)?
On an EBIT basis the return on assets of The Joint Corp is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of The Joint Corp (JYNT)?
The operating margin of The Joint Corp is 3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at The Joint Corp (JYNT)?
Revenue at The Joint Corp is growing +14.4% versus a year earlier (3y avg −18.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at The Joint Corp (JYNT)?
Earnings per share at The Joint Corp are growing +653% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does The Joint Corp (JYNT) hold?
The Joint Corp holds more cash than debt, $21.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch The Joint Corp in the live analysis
One click puts The Joint Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Oct 2, 2026